Cannabidiol Ameliorates Doxorubicin-Induced Myocardial Injury via Activating Hippo Pathway
- PMID: 39876987
- PMCID: PMC11774276
- DOI: 10.2147/DDDT.S497323
Cannabidiol Ameliorates Doxorubicin-Induced Myocardial Injury via Activating Hippo Pathway
Abstract
Background: Doxorubicin (DOX) is a chemotherapeutic agent widely used for cancer treatment and has non-negligible cardiotoxicity. Some previous studies have reported that cannabidiol (CBD) has cardioprotective effects. In this study, we evaluated the protective effects of CBD against DOX-induced cardiomyocyte injury, and explored the downstream molecular mechanism.
Methods and materials: GSE193861, containing healthy myocardial tissues and myocardial tissues with DOX-induced injury, was analyzed to screen for the involved proteins and pathways. Molecular docking was performed to identify candidate drugs. After H9c2 cells were treated with DOX and CBD, their viability, oxidative stress, and apoptosis were assessed. After YAP depletion, the role of the Hippo pathway in CBD function was investigated. C57BL/6 mice were treated with DOX to establish an in vivo model, and CBD and verteporfin (VP) were used to treat the mice. Histological analyses and immunofluorescence were used to evaluate myocardial tissue injury, and apoptosis and oxidative stress of the myocardial tissues were also analyzed. Western blotting was used to investigate the regulatory effects of CBD on the Hippo and apoptosis-related pathways.
Results: Bioinformatic analysis suggested that the Hippo pathway was a crucial pathway involved in DOX-induced myocardial injury. Molecular docking showed that CBD targeted multiple regulators of the Hippo pathway. CBD showed cardioprotective effects against DOX-induced myocardial injury both in vitro and in vivo and regulated Hippo pathway activity in cardiomyocytes. After inactivation of the Hippo pathway by YAP knockdown or VP intervention, the protective effects of CBD were reversed.
Conclusion: For the first time, we revealed that CBD is likely to reduce DOX-induced myocardial injury by regulating the Hippo signaling pathway.
Keywords: Hippo pathway; cannabidiol; doxorubicin; heart injury.
© 2025 Dong et al.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures







Similar articles
-
AMPK/PGC1α activation by melatonin attenuates acute doxorubicin cardiotoxicity via alleviating mitochondrial oxidative damage and apoptosis.Free Radic Biol Med. 2018 Dec;129:59-72. doi: 10.1016/j.freeradbiomed.2018.08.032. Epub 2018 Aug 30. Free Radic Biol Med. 2018. PMID: 30172748
-
Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress.Biochem Biophys Res Commun. 2020 Dec 10;533(3):304-312. doi: 10.1016/j.bbrc.2020.09.035. Epub 2020 Sep 18. Biochem Biophys Res Commun. 2020. PMID: 32958254
-
Serum and glucocorticoid inducible kinase 1 modulates mitochondrial dysfunction and oxidative stress in doxorubicin-induced cardiomyocytes by regulating Hippo pathway via Neural precursor cell-expressed developmentally down-regulated 4 type 2.Hum Exp Toxicol. 2023 Jan-Dec;42:9603271231158039. doi: 10.1177/09603271231158039. Hum Exp Toxicol. 2023. PMID: 36781297
-
Cannabidiol Protects against Doxorubicin-Induced Cardiomyopathy by Modulating Mitochondrial Function and Biogenesis.Mol Med. 2015 Jan 6;21(1):38-45. doi: 10.2119/molmed.2014.00261. Mol Med. 2015. PMID: 25569804 Free PMC article.
-
Dehydroevodiamine Alleviates Doxorubicin-Induced Cardiomyocyte Injury by Regulating Neuregulin-1/ErbB Signaling.Cardiovasc Ther. 2024 Dec 7;2024:5538740. doi: 10.1155/cdr/5538740. eCollection 2024. Cardiovasc Ther. 2024. PMID: 39742014 Free PMC article.
Cited by
-
Cannabidiol as an immune modulator: A comprehensive review.Saudi Pharm J. 2025 May 23;33(3):11. doi: 10.1007/s44446-025-00005-7. Saudi Pharm J. 2025. PMID: 40407987 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources